Welcome to our dedicated page for Ocugen news (Ticker: OCGN), a resource for investors and traders seeking the latest updates and insights on Ocugen stock.
Ocugen, Inc. develops gene therapies for blindness diseases through a modifier gene therapy platform designed to address inherited and multifactorial retinal disorders. Company news commonly covers programs such as OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy secondary to dry age-related macular degeneration, and OCU410ST for Stargardt disease.
Recurring updates include clinical trial data and dosing milestones, clinical and regulatory disclosures, operating and financial results, investor presentations, convertible-note financing, shareholder voting matters, capital-structure actions, and governance matters tied to the company's Nasdaq-listed common stock.
Ocugen (NASDAQ: OCGN) reported positive preliminary 12-month data from the Phase 2 ArMaDa trial of OCU410 (AAV5-RORA) for geographic atrophy (GA) secondary to dry AMD.
Key 12-month results: 46% lesion growth reduction (medium+high dose vs control; p=0.015; N=23), 54% reduction for medium dose (p=0.02; N=10), a 50% responder rate (>50% lesion reduction vs control), and subgroup (N=14) showing 57% greater reduction. Phase 1 evaluable eyes (N=7) showed 60% slower EZ loss versus fellow eyes. No OCU410-related serious adverse events reported across Phase 1 and Phase 2 (60 patients). Company aims to start Phase 3 in 2026 and pursue a BLA in 2028.
Ocugen (NASDAQ: OCGN) will host a conference call and live webcast on Thursday, January 15, 2026 at 8:30 a.m. ET to discuss data from the first half of patients reaching one year after treatment in the OCU410 Phase 2 ArMaDa clinical trial. The event will feature KOLs and Ocugen executive leadership, including Dr. Arshad M. Khanani, Dr. Jay Chhablani, and Dr. Lejla Vajzovic.
Dial-in numbers: (800) 715-9871 (U.S.) and (646) 307-1963 (international); Conference ID: 7783588. A webcast and replay will be available on the company’s investor site events section.
Ocugen (NASDAQ: OCGN) published peer‑reviewed Phase 1 GARDian1 results for OCU410ST, a modifier gene therapy for Stargardt disease, reporting 12‑month safety, tolerability, and exploratory efficacy data.
Key findings in small Phase 1 cohort: 54% reduction in atrophic lesion growth in treated eyes versus fellow eyes, lesion expansion ~50% slower, treated eyes gained an average of +6 letters BCVA versus −1.5 letters in untreated eyes, 100% of treated eyes stabilized or improved, and no drug‑related serious adverse events. Phase 2/3 GARDian3 enrollment is expected to complete in Q1 2026 with a potential BLA filing in H1 2027.
Ocugen (NASDAQ: OCGN) announced that Dr. Shankar Musunuri, chairman and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026 from 9:45–10:25 a.m. PST in the Colonial Room, Mezzanine. Company executives will hold one-on-one meetings in San Francisco the week of January 12–15 to discuss strategy and partnership opportunities.
Ocugen said it is on a path toward filing three BLAs in the next two years, including a rolling BLA for OCU400 for retinitis pigmentosa in 2026. A live webcast will be available on the company events page and a limited-time replay will follow the presentation.
Ocugen (NASDAQ: OCGN) announced that Dr. Shankar Musunuri, chairman, CEO, and co-founder, will present at the Oppenheimer Movers in Rare Disease Summit at the Sofitel New York on Thursday, December 11, 2025. The presentation is a fireside chat titled "Fireside Chat with Aldeyra and Ocugen: Setting Sights on Inherited Retinal Dystrophies" scheduled for 9:45–10:05 a.m. ET in the Second Floor Ballroom, Track 1.
Ocugen said its executive team will also hold one-on-one investor meetings to review the company’s gene-modifier therapy platform, clinical development strategy, and expected catalysts in 2026.
Ocugen (NASDAQ: OCGN) announced that Chairman and CEO Dr. Shankar Musunuri will present at NobleCon21—Noble Capital Markets’ 21st Annual Emerging Growth Equity Conference in Boca Raton, FL.
The presentation and fireside chat are scheduled for Wednesday, December 3, 2025 at 1 p.m. ET in Presentation Room 2. Ocugen executive team members will hold one-on-one investor meetings to discuss the company's business and clinical development strategy for its modifier gene therapy platform and progress toward three BLAs in three years.
A high-definition webcast will be posted the following day and archived on the company's website, the NobleCon website, and Channelchek.com for 90 days.
Ocugen (NASDAQ: OCGN) provided a business update and reported third quarter 2025 results. The company closed a $20M registered direct offering in August and would receive an additional $30M if warrants are fully exercised, and reported $32.9M cash on hand as of September 30, 2025.
Clinical progress includes 50% enrollment in the OCU410ST Phase 2/3 GARDian3 trial with a path toward a 1H 2027 BLA filing and EMA acceptability of a single U.S. trial for MAA submission. OCU400 Phase 3 enrollment is nearing completion with planned BLA/MAA filings in 2026. Ocugen executed an exclusive license for OCU400 in South Korea with upfront/milestone payments and sales milestones projected to reach $180M in the first 10 years and a 25% royalty.
Ocugen (NASDAQ: OCGN) will hold a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 5, 2025 to discuss third quarter 2025 financial results and provide a business update. The company will issue a pre-market earnings announcement the same day.
Dial-in numbers: U.S. (800) 715-9871, international (646) 307-1963; Conference ID: 3029428. The webcast is available in the events section of the Ocugen investor site. A replay and archived webcast will be available for approximately 45 days after the event.
Ocugen (NASDAQ: OCGN), a biotechnology company focused on gene therapies for blindness diseases, announced its participation in three major industry conferences in October 2025. The company will present at the Cell & Gene Meeting on the Mesa, Chardan's 9th Annual Genetic Medicines Conference, and the 2025 Maxim Growth Summit.
CEO Dr. Shankar Musunuri highlighted the company's goal of achieving three BLAs in the next three years. Executive Vice President Abhi Gupta will present a company update at Meeting on the Mesa, while Dr. Musunuri will participate in panel discussions at the Chardan and Maxim conferences. The events will also include one-on-one meetings with company leadership.
Ocugen (NASDAQ: OCGN) has executed a licensing agreement with Kwangdong Pharmaceutical for the exclusive Korean rights to OCU400, its modifier gene therapy for retinitis pigmentosa (RP). The deal includes upfront fees and near-term development milestone payments of up to $7.5 million, plus potential sales milestones of $180 million or more in the first 10 years of commercialization.
The agreement features 25% royalties on net sales and Ocugen will manufacture the commercial supply. The Korean market represents approximately 7,000 RP patients, about 7% of the U.S. market. Ocugen is currently advancing OCU400 through Phase 3 clinical development with a target U.S. BLA filing in 2026, which Kwangdong will leverage for Korean regulatory approval.